ArticleMedicine2025
Identification of biomarkers and exploration of mechanisms for atopic dermatitis based on transcriptome and scRNA-seq data analysis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chaga Mushroom (Journal of microbiology and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases with complex pathogenesis and no effective treatment. This study aims to use bioinformatics methods to identify biomarkers and explore the mechanism for AD. We performed differential expression analysis based on transcriptome datasets GSE16161 and GSE32924. Next, the differentially expressed genes (DEGs) were subjected to Kyoto Encyclopedia of Genes and Genomes enrichment analysis. After integrating PPI network obtained from STRING database, we screened modular genes and identified candidate key genes by the MCC and degree algorithms. We selected genes with strong ROC performance and consistent expression levels as key genes, and constructed a nomogram to assess their potential as AD biomarkers. Finally, by analyzing the scRNA-seq dataset GSE180885, we identified the key cells associated with the key genes and conducted pseudotime analysis based on these key cells to explore the pathogenic mechanisms of AD. The results showed that 618 DEGs were identified and some important pathways, including Cytokine-Cytokine Receptor Interaction, Cell Cycle, Cell Adhesion Molecules and Calcium Signaling Pathway were screened out. Seven key genes were identified and they were CCNA2, CCNB1, KIF2C, CEP55, MELK, CDC20, and CCNB2. The nomogram analysis suggested that these key genes had the potential to serve as biomarkers for AD. Through scRNA-seq data analysis, we identified 9 cell subpopulations, with keratinocytes were identified as the key cells, and 6 out of 7 key genes showed significant expression in keratinocytes. Pseudotime analysis revealed that DEGs in keratinocytes played a vital role in the cellular differentiation process of AD. We successfully identified CCNA2, CCNB1, KIF2C, CEP55, MELK, CDC20, and CCNB2, as potential biomarkers for AD through transcriptomic and scRNA-seq data analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.